{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:26:54Z","timestamp":1791440814508,"version":"4.3.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031135","name":"Swedish-Norwegian Foundation for Equine Research","doi-asserted-by":"publisher","award":["H-19-47-479"],"award-info":[{"award-number":["H-19-47-479"]}],"id":[{"id":"10.13039\/100031135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising drugs for treatment of hyperinsulinemia in insulin-dysregulated (ID) horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Compare short-term effects of the SGLT2 inhibitor canagliflozin versus placebo on glucose and insulin responses during an oral sugar test (OST) and a forage-based feed challenge test (FCT), and to assess adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-two privately owned severely ID horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Horses were allocated (1:1:1) to receive canagliflozin (0.6 or 1.2\u00a0mg\/kg PO q24h) or placebo. The study included a 5-day baseline evaluation, a 4-week at-home double-blind treatment period, and a 5-day follow-up evaluation. During each clinical visit, an OST (day 3) and FCT (day 4) were performed to characterize glucose and insulin responses. Adverse effects were recorded. Data are presented as geometric least squares mean (95% CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Peak insulin concentrations (\u03bcIU\/mL) during the OST and the FCT were lower after treatment with canagliflozin 0.6 and 1.2\u00a0mg\/kg compared with placebo (P\u00a0\u2264\u00a0.01); OST: 122.0 (96.6-154.0) and 108.6 (85.6-137.8) vs 288.7 (227.1-366.9) and FCT: 78.3 (37.6-162.9) and 54.2 (25.7-114.5) vs 140.3 (68.5-287.3). Canagliflozin caused a dose-dependent increase in triglyceride concentrations (P\u00a0\u2264\u00a0.01). Post-treatment triglyceride concentrations were 0.5 (0.4-0.8), 1.3 (0.9-2.0), and 2.9 (1.9-4.4) mmol\/L for placebo, 0.6\u00a0mg\/kg, and 1.2\u00a0mg\/kg groups, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Canagliflozin effectively decreases hyperinsulinemia in ID horses but induces a dose-dependent increase in triglyceride concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag107","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:26:34Z","timestamp":1782581194000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-6365","authenticated-orcid":false,"given":"Johan","family":"Br\u00f6jer","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 750 07 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-0245","authenticated-orcid":false,"given":"Siv","family":"Hanche-Olsen","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1432 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-6961","authenticated-orcid":false,"given":"Constanze","family":"Fintl","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1432 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-9599","authenticated-orcid":false,"given":"Elin","family":"Svonni","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 750 07 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4432","authenticated-orcid":false,"given":"Ingunn Risnes","family":"Hellings","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1432 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-1538","authenticated-orcid":false,"given":"Cecilia","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Applied Animal Science and Welfare, Swedish University of Agricultural Sciences , 750 07 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6124-4015","authenticated-orcid":false,"given":"Sanna","family":"Lind\u00e5se","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 750 07 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2026062713262674800_ref1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tvjl.2017.11.011","article-title":"Paradigm shifts in understanding equine laminitis","volume":"231","author":"Patterson-Kane","year":"2018","journal-title":"Vet J"},{"key":"2026062713262674800_ref2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.tvjl.2007.07.003","article-title":"Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies","volume":"174","author":"Asplin","year":"2007","journal-title":"Vet J"},{"key":"2026062713262674800_ref3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/evj.13572","article-title":"Predictors of laminitis development in a cohort of nonlaminitic ponies","volume":"55","author":"Knowles","year":"2023","journal-title":"Equine Vet J"},{"key":"2026062713262674800_ref4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/jvim.15423","article-title":"ECEIM consensus statement on equine metabolic syndrome","volume":"33","author":"Durham","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026062713262674800_ref5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40265-017-0801-6","article-title":"Canagliflozin: a review in type 2 diabetes","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"2026062713262674800_ref6","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/jvim.16906","article-title":"Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: a randomized, placebo-controlled, double-blind, study","volume":"37","author":"Lind\u00e5se","year":"2023","journal-title":"J Vet Intern Med"},{"key":"2026062713262674800_ref7","doi-asserted-by":"publisher","first-page":"106894","DOI":"10.1016\/j.domaniend.2024.106894","article-title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series","volume":"90","author":"Sundra","year":"2025","journal-title":"Domest Anim Endocrinol"},{"key":"2026062713262674800_ref8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12917-019-1811-2","article-title":"The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies","volume":"15","author":"Meier","year":"2019","journal-title":"BMC Vet Res"},{"key":"2026062713262674800_ref9","doi-asserted-by":"publisher","first-page":"e70256","DOI":"10.1111\/jvim.70256","article-title":"Effects of the sodium-glucose cotransporter-2 inhibitor velagliflozin on insulin concentrations in horses with insulin dysregulation","volume":"39","author":"Thane","year":"2025","journal-title":"J Vet Intern Med"},{"key":"2026062713262674800_ref10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/eve.13924","article-title":"Oral sugar test responses to ertugliflozin in ten horses with insulin dysregulation","volume":"36","author":"Sundra","year":"2024","journal-title":"Equine Vet Educ"},{"key":"2026062713262674800_ref11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jvp.13470","article-title":"Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses","volume":"48","author":"Menzies-Gow","year":"2025","journal-title":"J Vet Pharmacol Ther"},{"key":"2026062713262674800_ref12","doi-asserted-by":"publisher","first-page":"e0203655","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PloS One"},{"key":"2026062713262674800_ref13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jvp.13476","article-title":"Pharmacokinetics and alterations in glucose and insulin levels after a single dose of canagliflozin in healthy Icelandic horses","volume":"48","author":"Michanek","year":"2025","journal-title":"J Vet Pharmacol Ther"},{"key":"2026062713262674800_ref14","doi-asserted-by":"publisher","first-page":"106412","DOI":"10.1016\/j.tvjl.2025.106412","article-title":"Canagliflozin: pharmacokinetics, tolerability and glucose\/insulin effects of supratherapeutic doses in healthy horses","volume":"313","author":"Michanek","year":"2025","journal-title":"Vet J"},{"key":"2026062713262674800_ref15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/eve.13738","article-title":"Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series","volume":"35","author":"Sundra","year":"2023","journal-title":"Equine Vet Educ"},{"key":"2026062713262674800_ref16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Vet J"},{"key":"2026062713262674800_ref17","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"2026062713262674800_ref18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a Meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2026062713262674800_ref19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes Rev"},{"key":"2026062713262674800_ref20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.2042-3306.1983.tb01826.x","article-title":"Relationship between condition score, physical measurements and body fat percentage in mares","volume":"15","author":"Henneke","year":"1983","journal-title":"Equine Vet J"},{"key":"2026062713262674800_ref21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.tvjl.2008.02.029","article-title":"Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies","volume":"179","author":"Carter","year":"2009","journal-title":"Vet J"},{"key":"2026062713262674800_ref22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/jvim.14799","article-title":"Relationship between beta-cell response and insulin sensitivity in horses based on the oral sugar test and the euglycemic Hyperinsulinemic clamp","volume":"31","author":"Lind\u00e5se","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026062713262674800_ref23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5455\/OVJ.2023.v13.i3.14","article-title":"Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors","volume":"13","author":"Kellon","year":"2023","journal-title":"Open Vet J"},{"key":"2026062713262674800_ref25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/evj.13944","article-title":"Sodium-glucose cotransporter 2 inhibitors in horses-magic bullet or latest fad?","volume":"55","author":"Sundra","year":"2023","journal-title":"Equine Vet J"},{"key":"2026062713262674800_ref26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2026062713262674800_ref27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2026062713262674800_ref28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13300-021-01104-z","article-title":"SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: a narrative review","volume":"12","author":"Janez","year":"2021","journal-title":"Diabetes Ther"},{"key":"2026062713262674800_ref29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1472-6823-13-58","article-title":"Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials","volume":"13","author":"Berhan","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"2026062713262674800_ref30","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"2026062713262674800_ref31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026062713262674800_ref32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.2042-3306.2010.00327.x","article-title":"Assessment of body fat in the pony: part II. Validation of the deuterium oxide dilution technique for the measurement of body fat","volume":"43","author":"Dugdale","year":"2011","journal-title":"Equine Vet J"},{"key":"2026062713262674800_ref33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2337\/dc19-2177","article-title":"Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose excretion","volume":"43","author":"Solis-Herrera","year":"2020","journal-title":"Diabetes Care"},{"key":"2026062713262674800_ref34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2026062713262674800_ref34a","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.anifeedsci.2005.06.008","article-title":"Studies on microbial efficiency from two cuts of ryegrass (Aberdart) with different proportions of sugars and protein","volume":"126","author":"Ud\u00e9n","year":"2006","journal-title":"Anim Feed Sci Tech"},{"key":"2026062713262674800_ref35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.anifeedsci.2012.06.002","article-title":"Equine digestion of diets based on haylage harvested at different plant maturities","volume":"177","author":"M\u00fcller","year":"2012","journal-title":"Anim Feed Sci Tech"},{"key":"2026062713262674800_ref36","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2019.3087","article-title":"Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement","volume":"321","author":"Juszczak","year":"2019","journal-title":"JAMA"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/3\/aalag107\/68633264\/aalag107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/3\/aalag107\/68633264\/aalag107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:26:35Z","timestamp":1782581195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag107\/8719598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag107","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aalag107"}}